Galderma Group
CHF 160.80Change from previous close: −3.04%Absolute change: −CHF 5.05
Valuation
Data as of October 1, 2026
Valuation multiples
- Market cap
- CHF 37.5B
- Enterprise value
- CHF 40.55B
- P/E (trailing 12 months)
- 52.9
- Forward P/E
- 28.8
- PEG
- 1.21
- Price/book
- 5.45
- Price/sales
- 6.33
- EV/EBITDA
- 29.3
- EV/revenue
- 6.85
Profitability and growth
- Gross margin
- 69.4%
- Operating margin
- 20.2%
- Net margin
- 14.6%
- ROE
- 10.8%
- ROA
- 5.4%
- Revenue growth (year over year)
- 27.7%
- Earnings growth (year over year)
- 130.7%
Financial health
- Total cash
- CHF 839M
- Total debt
- CHF 2.72B
- Debt/equity
- 0.33
- Current ratio
- 1.24
- Quick ratio
- 0.90
Dividends
- Annual dividend per share
- CHF 0.35
- Dividend yield
- 0.2%
- Payout ratio
- 12.1%
- Ex-dividend date
- April 24, 2026
Analysts and estimates
- Average price target
- CHF 196.40
- Median price target
- CHF 199.01
- High price target
- CHF 267.09
- Low price target
- CHF 131.43
- Number of analysts
- 17
- Consensus
- Buy
- Forward EPS
- CHF 5.58
- EPS estimate, current year
- CHF 3.88
Shares and trading
- Beta
- -0.11
- Average volume
- 521.83K
- Shares outstanding
- 233.19M
- Float
- 131.27M
- Institutional ownership
- 48.1%
- Insider ownership
- 21.0%